1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  11:39 2022-06-24 am EDT
100.56 EUR   +5.02%
06/24Sanofi On Pace for Largest Percent Increase Since November 2020 -- Data Talk
DJ
06/24European Stocks Join Global Rally, Closes Week in the Green
MT
06/24SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Friday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi's Dupixent wins U.S. approval for bigger use

05/20/2022 | 02:42pm EDT

May 20 (Reuters) - Sanofi on Friday won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the U.S. Food and Drug Administration said. (Reporting by Ludwig Burger; Additional reporting by Eva Mathews; Editing by Maju Samuel)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS, INC. 0.84% 612.49 Delayed Quote.-3.01%
SANOFI 5.02% 100.56 Real-time Quote.13.52%
All news about SANOFI
06/24Sanofi On Pace for Largest Percent Increase Since November 2020 -- Data Talk
DJ
06/24European Stocks Join Global Rally, Closes Week in the Green
MT
06/24SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Friday
MT
06/24European shares mark strong end to nervous week
RE
06/24Sanofi, GSK variant-specific COVID shot found effective against Omicron
RE
06/24Sanofi, GSK COVID-19 Bivalent Vaccine Candidate Shows 72% Efficacy Against Omicron in P..
MT
06/24Sanofi, GSK Target COVID-19 Vaccine Availability in Late-2022 After New Positive Late-s..
MT
06/24Sanofi-GSK's COVID-19 Jab 72% Effective Against Omicron Variant in Late-stage Study
MT
06/24Sanofi says COVID-19 vaccine candidate yields positive trial data
RE
06/24Availability of the Q2 2022 Memorandum for modelling purposes
GL
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2022 41 842 M 44 137 M 44 137 M
Net income 2022 7 857 M 8 288 M 8 288 M
Net Debt 2022 6 634 M 6 998 M 6 998 M
P/E ratio 2022 15,8x
Yield 2022 3,51%
Capitalization 126 B 132 B 132 B
EV / Sales 2022 3,16x
EV / Sales 2023 2,93x
Nbr of Employees 95 442
Free-Float 88,0%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 100,56 €
Average target price 114,81 €
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI13.52%132 461
JOHNSON & JOHNSON5.02%479 678
ELI LILLY AND COMPANY13.21%293 110
PFIZER, INC.-15.17%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202